This observation could have clinical interest, and although it was limited to one patient and should be interpreted with caution, we confirmed the reduction of PD-L1 expression and the increase in sensitivity to eNK cytotoxicity mediated by idelalisib in the B-CLL cell line Mec-1. This evidence concerns the gene CD274 and B-cell chronic lymphocytic leukemia.